Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis
Clinical Lung Cancer · 2026-07 · 27 (6) · 50-57
DOI: 10.1016/j.cllc.2026.05.008 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2026-07. Verfasst von Yang Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Radiation Pneumonitis, Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Xiangya Hospital, Central South University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND For patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with neoadjuvant immuno-chemotherapy followed by definitive radiotherapy, the risk of radiation pneumonitis (RP) may be elevated. This multicenter study aimed to validate established dose-volume predictors in this specific treatment context. METHODS We analyzed 372 stage III NSCLC patients from 9 institutions who received neoadjuvant (NEO) or adjuvant immunotherapy. RP was graded per CTCAE v5.0. Univariable and multivariable logistic regression identified factors associated with grade ≥ 2 (RP2) and grade ≥ 3 (RP3) RP within the NEO cohort. Optimized dosimetric thresholds were derived using ROC curves. RESULTS In the NEO cohort, multivariable analysis showed lung V20 independently predicted RP2 (odd ratio [OR]: 1.09, 95% confidence interval [CI]: 1.05-1.14, P < .001), while mean lung dose (MLD) independently predicted RP3 (OR: 1.11, 95% CI, 1.02-1.22, P = .018). The optimal cutoffs were V20 ≤ 24% and MLD ≤ 14 Gy. A composite constraint (V20 ≤ 24% and MLD ≤ 14 Gy) significantly reduced RP2 (20.8% vs. 49.5%) and RP3 (8.2% vs. 23.1%) incidence compared to non-compliant plans. This new constraint showed significant net reclassification improvement for RP2 (NRI = 17.4%, P = .027) over conventional criteria (V20 ≤ 35%, MLD ≤ 20 Gy). CONCLUSION Stricter dosimetric constraints (V20 ≤ 24%; MLD ≤ 14 Gy) are critical for mitigating RP risk in stage III NSCLC patients treated with neoadjuvant immuno-chemotherapy and radiotherapy, providing tailored guidance for planning in the immunotherapy era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, China.
- Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electroni…
- Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, China.
- Department of Radiation Oncology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Chin…
- The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China; State Key Laboratory of Respiratory Disease, Department of Allergy and Clinical Immunology, Guangzhou Institute of Respira…
- Department of Oncology, Xiangxi Autonomous Prefecture People's Hospital, Ji Shou University, Jishou, China.
Förderung
- Xiangya Hospital, Central South University
Zitieren
APA
Liu, Y., Qi, Y., Pan, W., Bai, W., Chen, Y., Zhou, H., Liu, C., Xi, P., Li, X., Hou, L., Tao, X., Xia, Y., Zhang, X., & Song, Z. (2026). Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis. Clinical Lung Cancer, 27(6), 50-57. https://doi.org/10.1016/j.cllc.2026.05.008
Vancouver
Liu Y, Qi Y, Pan W, Bai W, Chen Y, Zhou H, et al. Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis. Clinical Lung Cancer. 2026;27(6):50-57. doi:10.1016/j.cllc.2026.05.008
BibTeX
@article{Liu2026,
author = {Liu, Yang and Qi, YunXiang and Pan, Wenyan and Bai, Wei and Chen, Yaoxin and Zhou, Hao and Liu, Chaoyuan and Xi, Pan and Li, Xiaoyan and Hou, Liangxue and Tao, Xuan and Xia, Yaoxiong and Zhang, Xi and Song, Zewen},
title = {Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis},
journal = {Clinical Lung Cancer},
year = {2026},
volume = {27},
number = {6},
pages = {50--57},
doi = {10.1016/j.cllc.2026.05.008}
}
EUVIMED